➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,539,302

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,539,302 protect, and when does it expire?

Patent 9,539,302 protects NOCTIVA and is included in one NDA.

This patent has sixty-five patent family members in nineteen countries.

Summary for Patent: 9,539,302
Title:Safe desmopressin administration
Abstract: Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.
Inventor(s): Fein; Seymour (New Canaan, CT)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/378,778
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,539,302
Patent Claim Types:
see list of patent claims
Composition; Device;

Drugs Protected by US Patent 9,539,302

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Roivant NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Roivant NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,539,302

PCT Information
PCT FiledJune 15, 2010PCT Application Number:PCT/US2010/038663
PCT Publication Date:December 23, 2010PCT Publication Number: WO2010/147981

International Family Members for US Patent 9,539,302

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009330203 ⤷  Free Forever Trial
Australia 2010260211 ⤷  Free Forever Trial
Australia 2015261630 ⤷  Free Forever Trial
Australia 2016204306 ⤷  Free Forever Trial
Australia 2017276227 ⤷  Free Forever Trial
Brazil PI0923557 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.